2025 Cell Therapy Processing Industry Trends Report: Long-Term Outlook Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Cell Therapy Processing Market Size By 2025?
The market for processing cell therapies has seen a swift expansion in recent times. The market is projected to escalate from $4.54 billion in 2024 to $5.18 billion in 2025, clocking a compounded annual growth rate (CAGR) of 14.3%. Factors driving growth during the historical period include heightened acceptance of therapies based on cells, increased investment in biomanufacturing infrastructure, growing demand for tailored medicine, successful clinical outcomes of cell therapies, and an upsurge in the necessity for good manufacturing practices (GMP)-compliant processing systems.

How Big Is the Cell Therapy Processing Market Size Expected to Grow by 2029?
The market for cell therapy processing is predicted to expand significantly in the upcoming years, reaching a value of $8.73 billion in 2029, reflecting a compound annual growth rate (CAGR) of 13.9%. The surge during the projection period could be due to the growing emphasis on automated cell processing technologies and the integration of artificial intelligence (AI) into cell manufacturing processes. Additionally, factors like the rising demand for scalable allogeneic cell therapies, increased regulatory backing for advanced therapy production, and growing collaborations between biotech companies and contract development and manufacturing organizations (CDMOs) also contribute to this growth. The forecast period is also expected to witness trends such as advancements in closed-system bioreactor technologies, the creation of real-time monitoring tools for cell cultures, progress in cell storage methods and cryopreservation, improvements in cell separation and purification techniques, and the emergence of modular and scalable good manufacturing practices (GMP) manufacturing platforms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cell-therapy-processing-global-market-report

Which Key Market Drivers Powering Cell Therapy Processing Market Expansion and Growth?
The cell therapy processing market is predicted to expand due to an uptick in cellular therapy research initiatives. Cellular therapy is a medical process utilizing therapeutic products derived from living cells, used to manage or treat variety of health conditions like cancers, genetic disorders and autoimmune diseases. Increasing needs for manufacturing platforms that are scalable, consistent and can handle high cell densities without compromising product quality have led to a surge in demand for cell-based therapies. Cell therapy processing provides a great advantage to cell therapy research. It aids in standardizing preparation, quality check and large-scale production of high quality cells, ensuring consistent and dependable results in both experimental and clinical studies. As per the International Federation of Pharmaceutical Manufacturers and Associations, a not-for-profit entity based in Switzerland, in December 2024, six pioneering cell and gene treatments were launched in 2023, marking a 50% increase compared to the three launched in 2022. This rise in cellular therapeutic research initiatives is hence contributing to the growth of the cell therapy processing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27244&type=smp

What Are the Key Trends Driving Cell Therapy Processing Market Growth?
Primary firms in the cell therapy processing market are channeling their efforts towards the creation of cutting-edge solutions such as integrated bioreactor-centrifuge systems. The aim is to enhance manufacturing procedures and elevate the uniformity, scalability, and sterility of cell-based treatments. Essentially, an integrated bioreactor-centrifuge system is a consolidated gadget that merges cell incubation and centrifugal separation within one closed module, permitting continual, automated cell processing without intermediate transfers. As a case in point, Limula SA, a company based in Switzerland specializing in cell and gene therapy production, unveiled LimONE in March 2025. This ground-breaking system amalgamates hardware, single-use consumables, and protocol-driven software to streamline intricate cell processing stages like incubation, centrifugation, and reagent handling into a single compact unit. This facilitates uniform, scalable manufacturing of therapies such as CAR-T and gene-edited stem cells from research to Good Manufacturing Practice (GMP)-compliant production, eliminating the necessity for complicated technology transfers.

What Are the Emerging Segments in the Cell Therapy Processing Market?
The cell therapy processing market covered in this report is segmented

1) By Offering Type: Products, Services, Software
2) By Applications: Cardiovascular Devices, Bone Repair, Neurological Disorders, Skeletal Muscle Repair, Cancer, Other Applications
3) By End-User: Research Institutes, Biopharmaceutical Companies, Contract Research Organizations, Other End-Users

Subsegments:
1) By Products: Cell Processing Systems, Cell Separation Devices, Cell Culture Equipment, Cell Preservation Systems, Consumables And Reagents
2) By Services: Contract Manufacturing Services, Process Development Services, Quality Control And Testing Services, Logistics And Supply Chain Services, Regulatory Compliance And Documentation Services
3) By Software: Cell Processing Workflow Management Software, Data Analysis And Reporting Software, Quality Management Software, Laboratory Information Management Systems (LIMS), Compliance And Audit Management Software

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27244&type=smp

Who Are the Global Leaders in the Cell Therapy Processing Market?
Major companies operating in the cell therapy processing market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, Gilead Sciences Inc., Danaher Corporation, Lonza Group AG, Anterogen Co. Ltd., Terumo Corporation, Sartorius AG, Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmbH, AGC Biologics S.p.A., MaxCyte Inc., Nkarta Inc., Cellares Corporation, Cellectis S.A., JW (Cayman) Therapeutics Company Limited, Cell Therapies Pty Ltd., and InGeneron Inc.

Which are the Top Profitable Regional Markets for the Cell Therapy Processing Industry?
North America was the largest region in the cell therapy processing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy processing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27244

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.